| Literature DB >> 10363966 |
M Grooteclaes1, D Vernimmen, S Plaza, F Pasleau, D Hodzic, R Winkler-Gol.
Abstract
The HER2 proto-oncogene product is overexpressed in 30% of breast cancers, and this correlates with poor prognosis. Increased levels of HER2 mRNA in breast cancer cell lines result from increased gene transcription. We report the identification of a new 17-bp-long cis sequence located between positions -506 and -489 from the transcription start site. This sequence is recognized by a trans-activating factor that we tentatively named HER2 transcription factor (HTF). This factor, involved in the increased transcription of the HER2 gene in the BT-474 mammary tumor cells, has a molecular weight of about Mr 50,000. HTF can also bind, but with a lower affinity, to a related cis sequence present in the epidermal growth factor receptor promoter. Interestingly, the HTF binding activity is high in nuclear extracts from several mammary tumor cells overexpressing the HER2 gene.Entities:
Mesh:
Substances:
Year: 1999 PMID: 10363966
Source DB: PubMed Journal: Cancer Res ISSN: 0008-5472 Impact factor: 12.701